A decade of data for the uk multiple sclerosis risk-sharing scheme.
Duddy M., Palace J.
The UK Multiple Sclerosis Risk-sharing Scheme (RSS) was established in 2002 following NICE's decision that the cost-effectiveness of interferon (IFN)-β and glatiramer acetate (GA) could not be assessed with existing short-term data. The scheme was set up as a joint undertaking between the Department of Health and the manufacturers of the drugs with input from other stakeholders. The purpose was to ensure cost-effective provision of IFNβ/GA to eligible people through a number of mechanisms, including an initial recalculation of drug pricing and the establishment of specialist nursing and medical structures. One aspect of the scheme was the enrolment of a cohort of at least 5000 people commencing IFNβ/GA with follow-up for 10 years, using these data to adjust drug costs.